Tag Archives: AMGN

Best Biotech Stocks To Own For 2018

Media coverage about Biogen (NASDAQ:BIIB) has been trending somewhat positive recently, according to Accern Sentiment Analysis. The research group identifies positive and negative media coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable.....More>>>

Top 10 Biotech Stocks To Watch For 2018

&l;p&g;&l;img class=&q;dam-image shutterstock size-large wp-image-659769976&q; src=&q;https://specials-images.forbesimg.com/dam/imageserve/659769976/960×0.jpg?fit=scale&q; data-height=&q;634&q; data-width=&q;960&q;&g; Shutterstock

It&s;s the unusually diverse nature of the list that&s;s fascinating. Lots of different types of industries and sectors. Some are reasonably well-known, others....More>>>

Hot Biotech Stocks To Invest In 2018

We have been long Novartis (NVS) for over a year now and its first quarter earnings report did nothing to change our long-term view. Wall Street didn’t take too kindly to the sequential decline in sales of cosentyx, which made shares drop to below $75 a share in the aftermath. However, shares have now printed a weekly swing low, which may mean the bottom is in.

Question marks surrounding....More>>>

Top 5 Biotech Stocks To Own Right Now

Strong minds discuss ideas, average minds discuss events, weak minds discuss people.” – Socrates

I received an inquiry from a real-time follower yesterday around an “off the radar” concern that rarely comes up in conversation but it is a name I own a few shares in. Given it is selling right at the same level as it was when I did an exclusive “first look”....More>>>

Top 5 Biotech Stocks To Own Right Now

As expected, the year’s first unicorn was a winner. Cybersecurity provider Zscaler (Pending:ZS) priced well above its range and shot up 106% on its debut. That’s good news for next week’s Dropbox (Pending:DBX). Investors are paying up for growth, which should lure even more unicorns to market. This past week also saw the year’s first bank IPO and the year’s largest....More>>>

Best Biotech Stocks To Watch For 2018

The Manufacturing sector saw plenty of trading activity today, including the following leaders and losers.

Some of the biggest gainers among Manufacturing stocks include:

Flex Pharma Inc Cmn (FLKS): FLKS stock is up 13.55% today. Egalet Corporation (EGLT): EGLT stock is up 12.41% today. Versartis Inc Cmn (VSAR): VSAR stock is up 10.15% today. Dynavax Technologies (DVAX): DVAX stock....More>>>

Top 5 Biotech Stocks To Invest In Right Now

Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication.

Welcome to another edition of “3 Things In Biotech You Should Learn Today,” a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research.

Merck buys into oncolytic virus therapy

Company: Merck (MRK)


Hot Biotech Stocks To Invest In 2018

Deals and Financings

Tianjin Tasly Pharma (SHA: 600535) is in talks to IPO its biopharma division in Hong Kong later this year with the goal of raising $1 billion. If it happens, the IPO will probably be Hong Kong’s largest biopharma IPO this year. Tasly, known for its TCM offerings, has been actively using M&A to expand into biologics. It has also invested in C-Bridge Capital’s....More>>>

Why Spectrum Pharmaceuticals, Inc. Is Up Big Today

In response to the company sharing more details of a phase 3 study with investors, shares ofSpectrum Pharmaceuticals(NASDAQ:SPPI), a small-cap biotech focused onhematology and oncology, jumped 16% as of 12:40 p.m. EDT onThursday.

So what

The study in questionis called ADVANCE. This phase 3 trial was designed to demonstrate noninferiority of Spectrum’s drug Rolontis when compared....More>>>

Your Daily Pharma Scoop: Loxo Outstanding Results, Cimzia Trial Success, Audentes Positive Data

Analysis focus: LOXO

Loxo Oncology (NASDAQ:LOXO), which was recently covered in a series of excellent articles by our very own Dr. Zach Hartman, PhD, who collaborates with the Total Pharma Tracker and whose members saw an early view of the series (…and so on), is up strongly following preliminary results which showed that its new LOXO-292 experimental cancer drug led to tumor shrinkage....More>>>